본문 바로가기
KERD
논문KCI 등재

Next-Generation Sequencing in Breast Cancer Patients: Real-World Data for Precision Medicine

조윤아|김덕근|조은윤|이현우
대한암학회 (Korean Cancer Association)|2024.01|Cancer Research and Treatment|제56권 제1호|pp. 149-161|DOI 10.4143/crt.2023.800

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

Breast neoplasmsNext-generation sequencingPrecision medicineBRCA1BRCA2PIK3CAESR1
주제분류의학일반

초록

Purpose Breast cancer is one of the most common causes of cancer-related death in females. Numerous drug-targetable biomarkers and predictive biomarkers have been developed. Some researchers have expressed doubts about the need for next-generation sequencing (NGS) studies in daily practice. This study analyzed the results of NGS studies on breast cancer at a single institute and evaluated the real-world applications of NGS data to precision medicine for breast cancer.Materials and Methods We retrospectively collected the results of NGS studies and analyzed the histopathologic features and genetic profiles of patients treated for breast cancer from 2010 to 2021. Seventy cases had data from CancerSCAN, a customized panel of 375 cancer-associated genes, and 110 cases had data from TruSight Oncology 500.Results The most frequently detected single nucleotide variant was the <i>TP53</i> mutation (123/180, 68.3%), followed by <i>PIK3CA</i> muta-tions (51/180, 28.3%). Estrogen receptor 1 (<i>ESR1</i>) mutation was detected in 11 patients (6.1%), of whom 10 had hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer, and two had no history of prior endocrine therapy. Based on their NGS study results, 13 patients (7.2%) received target therapy. Among them, four patients had a <i>BRCA1</i> or <i>BRCA2</i> germline mutation, and nine patients had a <i>PIK3CA</i> mutation.Conclusion NGS can provide information about predictive biomarkers and drug-targetable biomarkers that can enable treatment and participation in clinical trials based on precision medicine. Further studies should be conducted to excavate novel drug-targetable biomarkers and develop additional target therapies.

Abstract

Purpose Breast cancer is one of the most common causes of cancer-related death in females. Numerous drug-targetable biomarkers and predictive biomarkers have been developed. Some researchers have expressed doubts about the need for next-generation sequencing (NGS) studies in daily practice. This study analyzed the results of NGS studies on breast cancer at a single institute and evaluated the real-world applications of NGS data to precision medicine for breast cancer. Materials and Methods We retrospectively collected the results of NGS studies and analyzed the histopathologic features and genetic profiles of patients treated for breast cancer from 2010 to 2021. Seventy cases had data from CancerSCAN, a customized panel of 375 cancer-associated genes, and 110 cases had data from TruSight Oncology 500. Results The most frequently detected single nucleotide variant was the TP53 mutation (123/180, 68.3%), followed by PIK3CA muta-tions (51/180, 28.3%). Estrogen receptor 1 (ESR1) mutation was detected in 11 patients (6.1%), of whom 10 had hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer, and two had no history of prior endocrine therapy. Based on their NGS study results, 13 patients (7.2%) received target therapy. Among them, four patients had a BRCA1 or BRCA2 germline mutation, and nine patients had a PIK3CA mutation. Conclusion NGS can provide information about predictive biomarkers and drug-targetable biomarkers that can enable treatment and participation in clinical trials based on precision medicine. Further studies should be conducted to excavate novel drug-targetable biomarkers and develop additional target therapies.

참고문헌 (36)

  1. Choi JE, "Breast cancer statistics in Korea, 2019", J Breast Cancer, 26, pp.207~220 (2023)
  2. Hudis CA, "Trastuzumab : mechanism of action and use in clinical practice", N Engl J Med, 357, pp.39~51 (2007)
  3. Modi S, "Trastuzumab deruxtecan in previously treated HER2positive breast cancer", N Engl J Med, 382, pp.610~621 (2020)
  4. Osborne CK, "Tamoxifen in the treatment of breast cancer", N Engl J Med, 339, pp.1609~1618 (1998)
  5. Finn RS, "The cyclin-dependent kinase 4", 6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer(PALOMA-1, Lancet Oncol, pp.2015, 16[DOI]
  6. Schmid P, "Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer", N Engl J Med, 379, pp.2108~2121 (2018)
  7. Cortes J, "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer(KEY NOTE-355) : a randomised, placebo-controlled, double-blind, phase 3 clinical trial", Lancet, 396, pp.1817~1828 (2020)
  8. Giaquinto AN, "Breast cancer statistics, 2022", CA Cancer J Clin, 72, pp.524~541 (2022)
  9. Shin HC, "Detection of germline mutations in breast cancer patients with clinical features of hereditary cancer syndrome using a multi-gene panel test", Cancer Res Treat, 52, pp.697~713 (2020)
  10. Han SA, "The Korean Hereditary Breast Cancer(KOHBRA)study : protocols and interim report", Clin Oncol(R Coll Radiol), 23, pp.434~441 (2011)
  11. Sparano JA, "Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer", N Engl J Med, 379, pp.11121~ (2018)
  12. Piccart M, "70-gene signature as an aid for treat ment decisions in early breast cancer : updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age", Lancet Oncol, 22, pp.476~488 (2021)
  13. Li SY, "PIK3CA mutations in breast cancer are associated with poor outcome", Breast Can cer Res Treat, 96, pp.91~95 (2006)
  14. Wang T, "HER2somatic mutations are associated with poor survival in HER2negative breast cancers", Cancer Sci, 108, pp.671~677 (2017)
  15. Toy W, "ESR1ligand-binding domain mutations in hormone-resistant bre ast cancer", Nat Genet, 45, pp.1439~1445 (2013)
  16. Zheng ZY, "Neurofibromin is an estrogen receptor-alpha transcriptional co-repressor in breast cancer", Cancer Cell, 37, pp.387~402 (2020)
  17. Mosele F, "Recommendations for the use of next-genera tion sequencing(NGS)for patients with metastatic cancers : a report from the ESMO Precision Medicine Working Group", Ann Oncol, 31, pp.1491~1505 (2020)
  18. Amin MB, "AJCC cancer staging manual", pp.589~628 (2017), Springer
  19. Pereira B, "The somatic mutation profiles of 2, 433breast cancers refines their genomic and transcriptomic land scapes", Nat Commun, 7, pp.11479~ (2016)
  20. Curtis C, "The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups", Nature, 486, pp.346~352 (2012)
  21. Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours", Nature, 490, pp.61~70 (2012)
  22. Cerami E, "The cBio cancer genomics portal : an open platform for exploring multidimensional cancer genomics data", Cancer Discov, 2, pp.401~404 (2012)
  23. Gao J, "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal", Sci Signal, 6, pp.pl1~ (2013)
  24. Chakravarty D, "OncoKB: a precision oncology knowledge base", JCO Precis Oncol, 2017, pp.PO.17.00011~ (2017)
  25. Andre F, "Alpelisib for PIK3CA-mutated, hormone receptor positive advanced breast cancer", N Engl J Med, 380, pp.192940~ (2019)
  26. Dogruluk T, "Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations", Cancer Res, 75, pp.5341~5354 (2015)
  27. Ludwig KK, "Risk re duction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review", Am J Surg, 212, pp.660~669 (2016)
  28. Jeselsohn R, "ESR1 mutations : a mechanism for acquired endocrine resist ance in breast cancer", Nat Rev Clin Oncol, 12, pp.573~583 (2015)
  29. Jeselsohn R, "Emergence of con stitutively active estrogen receptor-alpha mutations in pre treated advanced estrogen receptor-positive breast cancer", Clin Cancer Res, 20, pp.1757~1767 (2014)
  30. Robinson DR, "Activating ESR1 mutations in hormone-resistant metastatic breast cancer", Nat Genet, 45, pp.1446~1451 (2013)
  31. Bidard FC, "Elacestrant(oral selective estrogen receptor degrader)versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : results from the rand omized phase III EMERALD trial", J Clin Oncol, 40, pp.324656~ (2022)
  32. Marabelle A, "Association of tumour mutational bur den with outcomes in patients with advanced solid tumours treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study", Lancet Oncol, 21, pp.1353~1365 (2020)
  33. Winer EP, "Association of tumor mutational burden(TMB)and clinical outcomes with pembrolizumab(pembro)versus chemotherapy(chemo)in patients with metastatic triple negative breast cancer(mTNBC)from KEYNOTE-119", J Clin Oncol, 38(15 Suppl), pp.1013~ (2020)
  34. Barroso-Sousa R, "Prevalence and mutational determinants of high tumor mutation burden in breast cancer", Ann Oncol, 31, pp.387~394 (2020)
  35. McNulty SN, "Optimization of population frequency cutoffs for filtering common germline polymorphisms from tumor-only next generation sequencing data", J Mol Diagn, 21, pp.903~912 (2019)
  36. Suh KJ, "Clini cal application of next-generation sequencing in patients with breast cancer : real-world data", J Breast Cancer, 25, pp.366~378 (2022)

관련 논문AI추천

Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience고지원, 권소연, 김미소, 김시현, 김정호, 김종일, 김진용, 김태용, 김태유, 배정모, 서정민, 성문우, 송명근, 우고운, 원재경, 유한석, 윤홍석, 이경훈, 이대원, 이성영, 이지수, 이한백, 임석아, 전윤경, 최재용대한암학회 · Cancer Research and Treatment2025 · 제57권 제2호Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation강효은, 김열홍, 김주원, 박경화, 배수연, 유지영, 윤승규, 정승필, 최윤지, 최지미대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호PIK3CA Mutation Is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients김주원, 김철용, 박경화, 송성은, 유지영, 이남권, 이정현, 임아름, 정승필, 조규란대한암학회 · Cancer Research and Treatment2023 · 제55권 제2호Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer PatientsHong Zheng, Jiayuan Li, Jiemin Wang, Ling Deng, Min Hu, Xiaorong Zhong, Xuehua Zhu, Yun Sun대한암학회 · Cancer Research and Treatment2019 · 제51권 제1호Evaluation of a Targeted Next-generation Sequencing Assay for BRCA Mutation Screening in Clinical Samples김광중, 김만진, 김시은, 박성섭, 성문우, 송병주, 오은설, 이근숙, 이창선, 임지은, 조성임대한진단검사의학회 · Laboratory Medicine Online2021 · 제11권 제4호Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer김석원, 김지연, 남석진, 박경희, 박연희, 배수연, 안진석, 이광희, 이세경, 이은진, 이정언, 임영혁, 정혜현, 조은윤대한암학회 · Cancer Research and Treatment2016 · 제48권 제4호

이 간행물의 다른 논문 (30건)

Intensity-Modulated Radiation Therapy for Uterine Cervical Cancer to Reduce Toxicity and Enhance Efficacy – an Option or a Must?: A Narrative Review이세원, 이성종, 김성환, 김애란, 이종훈pp. 1-17Longitudinal Changes in Smoking Behaviors and Cancer-Related Mortality Risk in Middle-aged Korean Women김선주, 박보영, 김소연, TRANTHIXUANMAIpp. 18-26Trends and Clinical Characteristics of Next-Generation Sequencing-Based Genetic Panel Tests: An Analysis of Korean Nationwide Claims Data박해용, 임현선, 김은경, 최윤라, 심효섭, 장미, 허자윤pp. 27-36A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial김규현, 이근욱, 안희경, 김진수, 이윤규, 안호정, 임선민, 안명주, 김범석, 김혜련, 이현우pp. 37-47Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset왕장영, 이윤규, 신상원, 최진혁, 이종석, 김진수, 심병용, 김주항, 민영주, 이기형, 이영주, 박건욱, 고윤호, 김동완, 최석영, 강진형, 조은경, 이경원, 전상훈, 이성숙, 이경희, 김상위, 안명주, 조병철pp. 48-60
원문 보기